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esponsibility of Xi'aAbstract Investigation of charge-transfer (CT) complexes of drugs has been recognized as an important
phenomenon in understanding of the drug–receptor binding mechanism. Structural, thermal, morpholo-
gical and biological behavior of CT complexes formed between drug quinidine (Qui) as a donor and
quinol (QL), picric acid (PA) or dichlorodicyanobenzoquinone (DDQ) as acceptors were reported. The
newly synthesized CT complexes have been spectroscopically characterized via elemental analysis;
infrared (IR), Raman, 1H NMR and electronic absorption spectroscopy; powder X-ray diffraction
(PXRD); thermogravimetric (TG) analysis and scanning electron microscopy (SEM). It was found that the
obtained complexes are nanoscale, semi-crystalline particles, thermally stable and spontaneous. The
molecular composition of the obtained complexes was determined using spectrophotometric titration
method and was found to be 1:1 ratios (donor:acceptor). Finally, the biological activities of the obtained
CT complexes were tested for their antibacterial activities. The results obtained herein are satisfactory for
estimation of drug Qui in the pharmaceutical form.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.sity. Production and hosting by Elsev
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n Jiaotong University.1. Introduction
Considerable attention has recently been paid to the formation of
stable charge-transfer (CT) complexes that result from the reaction
between acceptors and drugs or biological compounds. This
interest stems from the signiﬁcant physical and chemical pro-
perties of these complexes. The CT complexation is an importantier B.V. All rights reserved.
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Scheme 1 Chemical structure of quinidine.
H.H. Eldaroti et al.82technique that is cheaper, simpler, and more efﬁcient than the
methods of drug determination described in the literature [1]. The
study of the CT complexes of drugs may be useful in under-
standing the drug–receptor interactions and the mechanisms of
drug action [2]. Furthermore, the crystalline CT complexes have a
vital role in biological systems such as antimicrobial activity and
DNA-binding. Literature shows that the CT complexes exhibit
potential antimicrobial properties against Gram-positive and
Gram-negative bacteria as well as fungi [3–9]. Herein, the CT
interaction between the drug quinidine and three acceptors is
reported. Quinidine (Qui; C20H24N2O2, Scheme 1) is a pharma-
ceutical agent that acts as a class I antiarrhythmic drug in the heart
[10]. It is a stereoisomer of quinine, originally derived from the
bark of the cinchona tree. Qui is well-known as medicinally
important compound [11–15]. It is used to treat and control atrial
ﬁbrillation and atrial ﬂutter. Qui is also approved to treat premature
ventricular contractions and paroxysmal atrial tachycardia or
paroxysmal atrioventricular junctional rhythm. It may also be used
to treat malaria, although quinine is preferred [16,17].
To provide the basic data that can be used to understand drug–
receptor mechanism, the CT complexes of Qui with quinol (QL),
picric acid (PA) and dichlorodicyanobenzoquinone (DDQ) were
synthesized and spectroscopically investigated. The newly synthe-
sized CT complexes have been structurally characterized via
elemental analysis; infrared (IR), Raman, 1H –NMR and electronic
absorption spectroscopy; powder X-ray diffraction (PXRD); and
scanning electron microscopy (SEM) to interpret the behavior of
the interactions. Finally, the biological activity of the CT
complexes was tested for their antibacterial activities.2. Materials and methods
2.1. Chemicals
All chemicals used were of analytical grade. Qui
((9S)-6′-methoxycinchonan-9-ol, C20H24N2O2; 324.417) and π-
acceptors of quinol (QL) (Benzene-1,4-diol; C6H6O2; 110.11),
picric acid (PA) (2,4,6-trinitrophenol; C6H3N3O7; 229.1) or DDQ
(2,3-dichloro-5,6-dicyano-1,4-benzoquinone; C8Cl2N2O2; 227)
were purchased from Merck Chemical Company and were used
without further puriﬁcation. Commercially available spectroscopic
grade solvents (BDH) were also used as received. The systematic
IUPAC names of the formed CT complexes are [(Qui)(QL)]
complex: 6′-methoxycinchonan-1-ium-9-ol-4-hydroxybenzenol-ate
(C26H30N2O4; 434.527); [(Qui)(PA)] complex: 6′-methoxycincho-
nan-1-ium-9-ol-2,4,6-trinitrobenzeno-late (C26H27N5O9; 553.517);[(Qui)(DDQ)] complex: 4,5-dichloro-2-cyano-3,6-dioxocyclohexa-
1,4-diene-1-carbonitrilium(9S)-6′-methoxycinchonan-9-olate (C28H24
Cl2N4O4; 551.417).2.2. Instruments
The elemental analyses of the carbon and hydrogen contents were
performed by the microanalysis facility at Cairo University, Egypt,
using a Perkin-Elmer CHN 2400 (USA). The electronic absorption
spectra of methanolic solutions of the donor, acceptors and
resulting CT complexes were recorded over a wavelength range
of 200–800 nm using a Perkin-Elmer Lambda 25 UV/vis double-
beam spectrophotometer at Taif University, Saudi Arabia. The
instrument was equipped with a quartz cell with a 1.0 cm path
length. The mid-infrared (IR) spectra (KBr discs) within the range
of 4000–400 cm1 for the solid CT complexes were recorded on a
Shimadzu FT-IR spectrophotometer with 30 scans at 2 cm1
resolution. The Raman laser spectra of the samples were measured
on a Bruker FT-Raman spectrophotometer equipped with a 50 mW
laser at Taif University, Saudi Arabia. 1H NMR spectra were
collected by the Analytical Center at King Abdul Aziz University,
Saudi Arabia, on a Bruker DRX-250 spectrometer operating at
250.13 MHz with a dual 5 mm probe head. The measurements
were performed at ambient temperature using DMSO-d6
(dimethylsulfoxide, d6) as a solvent and tetramethylsilane (TMS)
as an internal reference. The 1H NMR data are expressed in parts
per million (ppm) and are internally referenced to the residual
proton impurity in the DMSO solvent. Thermogravimetric analysis
(TG) was performed under an air atmosphere between room
temperature and 800 1C at a heating rate of 10 1C/min using a
Shimadzu TGA-50H thermal analyzer at the Central Lab at Ain
Shams University, Egypt. The X-ray diffraction patterns for the
obtained CT complexes were collected on a PANalytical X'Pert
PRO X-ray powder diffractometer at the Central Lab at Ain Shams
University, Egypt. The instrument was equipped with a Ge(III)
monochromator, and a Cu Kα1 X-ray source with a wavelength of
0.154056 nm was used. Scanning electron microscopy (SEM)
images were collected on a Jeol JSM-6390 instrument at Taif
University, Saudi Arabia. The instrument was operated at an
accelerating voltage of 20 kV.2.3. Procedures
2.3.1. Reaction procedure
The solid CT complexes of Qui with QL, PA or DDQ were
prepared by mixing equimolar amounts of Qui with each acceptor
in methanol (10 mL). The solutions were stirred for about 20 min,
and allowed to evaporate slowly at room temperature, which
resulted in the precipitation of the solid CT complexes. The
resultant complexes were ﬁltered off, washed well with little
amounts of methanol, and then collected and dried under vacuum
over anhydrous calcium chloride for 24 h.2.3.2. Preparation of standard stock solutions of the donor
and acceptors
Stock solutions of Qui and acceptors at a concentration of
5.0 103 M were freshly prepared before each series of mea-
surements by dissolving precisely weighed amounts in the appro-
priate volume of the methanol solvent. The stock solutions were
protected from light.
250 300 350 400
0.0
0.1
0.2
0.3
0.4
0.5
0.6
Qui-QL
290 nm (CT-band)
A
bs
or
ba
nc
e
Wavelength (nm)
QL
Qui
CT complex
300 400 500
0.0
0.5
1.0
1.5
2.0
Qui-PA
345 nm (CT-band)
A
bs
or
ba
nc
e
Wavelength (nm)
PA
Qui
CT complex
300 400 500 600
0.0
0.2
0.4
0.6
0.8
1.0
Qui-DDQ
280 and 394 nm (CT-bands)
A
bs
or
ba
nc
e
Wavelength (nm)
DDQ
Qui
CT complex
Fig. 1 Electronic absorption spectra of [(Qui)(QL)], [(Qui)(PA)] and [(Qui)(DDQ)] charge-transfer complexes in methanol solvent.
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Spectrophotometric titration measurements were carried out for the
reactions of Qui with QL, PA and DDQ against methanol as a
blank at wavelengths of 290, 345 and 394 nm, respectively.
A 0.25, 0.50, 0.75, 1.00, 1.50, 2.0, 2.50, 3.00, 3.50 or 4.00 mL
aliquot of a standard solution (5.0 104 M) of the appropriate
acceptor in methanol was added to 1.00 mL of 5.0 104 M Qui,
which was also dissolved in methanol. The total volume of the
mixture was 5 mL. The concentration of Qui (Cd) in the reaction
mixture was maintained at 5.0 104 M, whereas the concentra-
tion of the acceptors (Ca) changed over a wide range of
concentrations (0.25 104 M–4.00 104 M) to produce solu-
tions with an acceptor molar ratio that varied from 4:1 to 1:4. The
stoichiometry of the Qui CT complexes was obtained from the
determination of the conventional spectrophotometric molar ratio
according to known methods using a plot of the absorbance of
each CT complex as a function of the Cd:Ca ratio. Modiﬁed
Benesi–Hildebrand plots were constructed to allow the calculation
of the formation constant, KCT, and the absorptivity, εCT, values
for each CT complex in this work.
2.3.4. Biological assessment
The antibacterial activities of the newly synthesized Qui CT complexes
and the pure solvent were tested in vitro against two Gram-positive
bacteria, Staphylococcus aureus (MSSA 22) and Bacillus subtilis
(ATCC 6051), and two Gram-negative bacteria, Escherichia coli
(K 12) and Pseudomonas aeruginosa (MTCC 2488), using a modiﬁed
Bauer–Kirby disc diffusion method. The microanalysis facility at
Cairo University, Egypt performed the investigations. For theseinvestigations, 100 μL test bacteria were grown in 10 mL fresh
medium until they reached a count of approximately 108 cells/mL
for bacteria or 105 cells/mL for fungi. Then, 100 μL microbial
suspension was spread onto agar plates. The nutrient agar medium
for the antibacterial tests consisted of 0.5% peptone, 0.1% beef extract,
0.2% yeast extract, 0.5% NaCl and 1.5% agar-agar [18]. Isolated
colonies of each strain were selected from the primary agar plates and
tested for susceptibility. After the plates were incubated for 48 h at
37 1C, the inhibition (sterile) zone diameters (including the disc) were
measured using slipping calipers from the National Committee for
Clinical Laboratory Standards (NCCLS, 1993) [19] and are expressed
in mm. The screening was performed using 100 μg/mL CT complex.
An antibiotic disc of tetracycline (30 μg/disc, Hi-Media) was used as a
positive control.3. Results and discussion
3.1. Elemental analysis results
Elemental analysis (C and H) of the Qui CT complexes was
performed and the obtained results are as follows: [(Qui)(QL)]:
C26H30N2O4; Mol. wt.¼434.527; Brown; Calc.: %C, 71.36; %H,
7.12; Found: %C, 71.80; %H, 6.90, [(Qui)(PA)]: C26H27N5O9;
Mol. wt.¼553.517; Pale yellow; Calc.: %C, 55.91; %H, 4.53;
Found: %C, 56.37; %H, 4.88, [(Qui)(DDQ)]: C28H24Cl2N4O4;
Mol. wt.¼551.417; Dark greenish brown; Calc.: %C, 61.54; %H,
4.52; Found: %C, 60.93; %H, 4.35. The resulting values are in
good agreement with the calculated values, and the suggested
H.H. Eldaroti et al.84values are in agreement with the molar ratios determined from the
spectrophotometric titration curves. The stoichiometry of all Qui
complexes was found to be 1:1 ratios. Based on the obtained data,
the formed CT complexes were formulated as [(Qui)(QL)], [(Qui)
(PA)] and [(Qui)(DDQ)]. The formation of 1:1 complex was
strongly supported by IR, 1H NMR as well as thermal analysis.
3.2. Electronic absorption spectra
Fig. 1 shows the electronic spectra of Qui, acceptors and the formed
CT complexes. These spectra revealed the characterization of the real
absorption bands that are attributed to the CT interactions. These bands
are observed at 290, 345 and (280, 394) nm for the [(Qui)(QL)], [(Qui)
(PA)] and [(Qui)(DDQ)] complexes, respectively. The peak absorbance
values that appeared in the spectra assigned to the formed CT
complexes were measured and plotted as a function of the Cd:Ca ratio
according to a known method. Spectrophotometric titration plots based
on these characterized absorption bands (Fig. 2) conﬁrmed the complex
formation at a ratio (Qui: acceptor) of 1:1 in all cases. This result is
strongly supported by the elemental analyses. The formation constant
(KCT) and the extinction coefﬁcients (ε) of the Qui CT complexes were
calculated by applying the 1:1 Benesi–Hildebrand equation in Eq. (1).
ðCaCdÞ=A¼ 1=Kεþ ðCa þ CdÞ=ε ð1Þ
where Ca and Cd are the initial concentrations of the electron acceptor
(QL, PA or DDQ) and the electron donor (Qui), respectively, and A is
the absorbance of the strongly detected CT band. Plotting the (CaCd)/A
values versus the corresponding (Ca+Cd) values for the formed Qui CT
complexes, straight lines were obtained supporting our ﬁnding of the
formation of 1:1 complexes. In the plots, the slope and the intercept0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5
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Fig. 2 Spectrophotometric titration curves for Qui charge-traequal 1/ε and 1/Kε, respectively. The Benesi–Hildebrand plots are
shown in Fig. 3, and the values of Cd, Ca, (Cd+Ca) and (CdCa)/A are
listed in Table 1. The values of both KCT and ε associated with the
complexes are given in Table 2. These complexes exhibit high values
for both the formation constants (KCT) and the extinction coefﬁcients
(ε). The high values of KCT reﬂect the high stabilities of the formed CT
complexes as a result of the expected strong donation from the drug
Qui. The equilibrium constants are strongly dependent on the nature of
the used acceptor including the type of electron withdrawing sub-
stituent to it such as nitro and halo groups [20]. The data reveal that the
[(Qui)(DDQ)] complex exhibits a higher KCT value compared with the
other two complexes, reﬂecting the relatively higher powerful electron
acceptance ability for DDQ, which containing two cyano and two
chloro groups between two carbonyl groups. The data also reveal that
the [(Qui)(PA)] complex shows a higher value of ε. The ε values
of Qui CT complexes in decreasing order are [(Qui)(PA)]4[(Qui)
(DDQ)]4[(Qui)(QL)].3.3. Calculation of the spectroscopic and physical data
The spectroscopic and physical data, such as the standard free energy
(ΔG1), the oscillator strength (f), the transition dipole moment (μ), the
resonance energy (RN), and the ionization potential (IP), were estimated
for complexes dissolved in methanol at 25 1C. The oscillator strength
(f) is a dimensionless quantity used to express the transition probability
of the CT band. From the CT absorption spectra, the oscillator strength
(f) can be estimated using the approximate formula:
f ¼ 4:319 109
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R
εCT dν is the area under the curve of the extinction
coefﬁcient of the absorption band in question plotted as a function
of frequency. To a ﬁrst approximation,
f ¼ 4:319 109εCTν½ ð3Þ
where εCT is the maximum extinction coefﬁcient of the CT band,
and ν½ is the half-bandwidth in cm
1 (i.e., the bandwidth at half of
the maximum extinction coefﬁcient value). The transition dipole
moments (μ) of the Qui CT complexes have been calculated from
Eq. (4) [21]:
μ¼ 0:0958 ½εCTν½=νmax½ ð4Þ
The transition dipole moment (μ) can be used to determine if a
particular transition is allowed; the transition from a bonding π
orbital to an antibonding π* orbital is allowed because the integral
that deﬁnes the transition dipole moment is nonzero. The ioniza-
tion potentials (IP) of the Qui donor in the CT complexes were
calculated using the empirical equation derived by Aloisi and
Pignataro represented in Eq. (5):
IPðeVÞ ¼ 5:76þ 1:53 104νCT ð5Þ
where νCT is the wavenumber in cm
1 that corresponds to the
CT band formed from the interaction between the donor and the
acceptor. The electron-donating power of a donor molecule is
measured by its ionization potential, which is the energy required
to remove an electron from the highest occupied molecular orbital.
Briegleb and Czekalla theoretically derived the following relation-
ship to obtain the resonance energy (RN):
εCT ¼ 7:7 104=½hνCT= RN½ 3:5 ð6Þwhere εCT is the extinction coefﬁcient of the CT complex at the
maximum of the CT absorption, νCT is the frequency of the CT
peak, and RN is the resonance energy of the complex in the ground
state, which contributes to the stability constant of the complex (a
ground-state property). The energy values (ECT) of the n-π* and
π–π*interactions between the Qui donor and the acceptors were
calculated using the equation derived by Briegleb:
ECT ¼ ðhνCT Þ ¼ ð1243:667=λCT Þ ð7Þ
where λCT is the wavelength of the CT band. The standard free
energy of complexation (ΔG1) for each complex was calculated
from the formation constants using the equation:
ΔG1¼2:303RT logKCT ð8Þ
where ΔG1 is the standard free energy change of the CT
complexes (kJ/mol), R is the gas constant (8.314 J/mol K), T is
the absolute temperature in K, and KCT is the formation constant of
the complex (L/mol) at room temperature.
The calculated spectroscopic and physical values for the Qui
CT complexes using these Eqs. (2)–(8) are presented in Table 2.
The [(Qui)(DDQ)] complex exhibits considerably higher value of
oscillator strength (f), indicating a strong interaction between the
drug Qui and the DDQ acceptor. DDQ is a strong electron
acceptor to form stable CT complexes with the donors. The
calculated ionization potential (IP) value for the highest ﬁlled
molecular orbital that participates in the CT interaction of the Qui
donor is approximately 10.29. The obtained values of standard free
energy change (ΔG1) for the [(Qui)(QL)], [(Qui)(PA)] and [(Qui)
(DDQ)] are 35.722, 35.102 and 34.414 kJ/mol, respectively;
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H.H. Eldaroti et al.86these negative values indicate that the interaction between the Qui
and the acceptors is spontaneous [22,23].
3.4. Interpretation of IR and Raman spectra
The IR absorption spectra of the Qui solid CT complexes were
registered in the frequency range of 4000–400 cm1 using KBr
disc and their peak assignments for the important characteristic
bands are given in Table 3. The full IR and Raman spectra of the
Qui CT complexes are shown in Figs. 4 and 5, respectively. The
IR spectra of the [(Qui)(QL)] and [(Qui)(PA)] complexes are
characterized by a broad strong-to-medium band that appears at
2872 cm1 for the QL complex and at 2820 cm1 for the PA
complex, which does not appear in the spectra of the free Qui
donor or those of the QL and PA acceptors. These broadened
peaks are attributed to the stretching vibration of the intermole-
cular hydrogen bond formed through the transfer of proton from
the acidic center on the QL and PA acceptors to the basic center of
the Qui donor (lone pair of electrons on the N (1) atom) to form
+NH based on acid–base theory [24–29].
The IR and Raman spectra of the [(Qui)(DDQ)] complex
indicated that the band that results from the ν(CRN) vibration
of the free DDQ acceptor changed in frequency and decreased in
intensity in the complexes upon CT complexation. Free DDQ
shows two ν(CRN) vibration at 2250 and 2231 cm1, while in
its complex; ν(CRN) occurs at lower wavenumber values
(IR/Raman; 2209/2225 cm1). It is clear that ν(CRN) of DDQ
is decreased upon complexation. The characteristic band of ν(OH)
group observed at 2955 cm1 in the free Qui donor, is shifted in
the complex and its intensity is affected. The group of bands
assigned to ν(C–Cl) vibrations, which appeared at 893 and
800 cm1 in the free DDQ, exhibited a shift to lower wavenum-
bers at 862 and 780 cm1 and decreasing in the intensities of the
characteristic peaks. These observations clearly conﬁrm that the
(–OH) group in the Qui donor and the (–CRN) group in the
DDQ acceptor participated in the complexation process. Because
DDQ lacks acidic centers, the molecular complex can be con-
cluded to form through π-π* and/or n-π* charge migration from
the HOMO of the donor to the LUMO of the acceptor. The π-π*
CT complex is formed via the benzene ring (electron-rich group)
of the Qui and DDQ reagents (electron acceptor) [30]. The cyano
group (–CRN) is an electron-withdrawing group that exists in
DDQ in a conjugated bonding system. The 2CN groups in DDQ
withdraw electrons from the aromatic ring, and such a process will
make the aromatic ring an electron-accepting region. The π*–CN
electron density appears to increase and more easily accept a
proton from the donor because of the electron-withdrawing
process and the conjugated electron system. So, the interaction
mode between Qui and the DDQ acceptor also occurs through the
migration of a H+ ion to one of the cyano groups in the DDQ
acceptor to form a positive ion (–CRN+H) that associates with
the (–O) anion to form ion pairs [31,32].
3.5. Interpretation of 1H NMR spectra
The nuclear magnetic resonance spectra present the persuasive
conﬁrmation of the complexation pathway. Thus, the 400 MHz 1H
NMR spectra of the Qui CT complexes were measured in DMSO-
d6 at room temperature and are given in Fig. 6. The chemical shifts
(δ) of the different types of protons of the CT complexes are [(Qui)
(QL)] complex: δ¼1.32–1.37 (m, 5H, 2(CH2) at C(5), C(8) and
Table 2 Spectroscopic and physical data of the Qui CT complexes.
Complex λmax (nm) ECT (eV) KCT (L/mol) εmax (L/mol/cm) f μ Ip RN ΔG1 (25 1C) (kJ/mol)
[(Qui)(QL)] 290 4.29 1.83 104 1.80 104 15.51 30.92 11.04 1.21 35.7
[(Qui)(PA)] 345 3.60 1.42 104 5.10 104 22.03 40.20 10.20 1.03 35.1
[(Qui)(DDQ)] 394 3.16 2.07 104 3.47 104 37.32 17.68 9.64 0.85 34.4
Table 3 Infrared frequenciesa (cm1) and tentative assignments for Qui, acceptors and the formed CT complexes.
Qui QL PA DDQ [(Qui)(acceptor)] CT complexes Assignmentsb
QL PA DDQ
3070 mw 3262 br 3416 br 3325 w 3658 w 3053 w 3195 s, br ν(N–H)
2955 vs 3031 m 3103 ms 3218 br 3152 s, br 2976 m 3009 w ν(O–H)
3077 m 2949 s ν(C–H); aromatic
ν(+NH)
2854 vs, sh 2857 m 2980 sh 2250 vw 2938 vs 2880 mw 2209 ms νs(C–H)+νas(C–H)
2723 m, br 2872 w 2231 ms 2872 s, sh 2820 m, br Hydrogen bonding
ν(CRN); DDQ
1621 ms 1518 vs 1632 vs 1673 vs 1622 s 1613 vs 1622 s δdef(N–H); Qui, complex
1590 m 1608 vs 1552 vs 1591 m, sh 1566 s 1562 s νas(NO2); PA, complex
1510 s 1529 vs 1510 vs 1545 s, sh 1511 s ν(CQO)+ν(CQC)+ν(C–N)
1519 ms δ(C–H) deformation
1466 s 1477 vs 1432 s 1451 s 1468 m 1430 ms 1454 vs, sh ν(CQN); Qui, complex
1433 m, sh 1435 vs ν(CQC) (in-ring), aromatic
1263 s 1366 ms 1343 ms 1358 w 1363 m 1365 s 1265 m, sh ν(C–C)+ν(C–O)+νs(C–N)
1188 m 1244 vs 1150 ms 1267 s 1329 mw 1321 vs 1240 vs C–H in-plane bending
1106 m 1222 vs 1086 s 1172 vs 1239 vs 1268 s 1080 ms νsNO2; PA, complex
1076 m 1210 vs 1072 w 1028 s 1245 m, sh 1029 ms
1051 ms 1164 ms 1010 vw 998 m 1164 m 989 mw
1020 m 1097 m 1033 m
857 ms 827 s 917 vs 893 s 916 m 917 ms 888 m δrock, NH
821 ms 759 vs 781 s 800 vs 836 s 865 m 862 m ν(C–Cl); DDQ, complex
715 m 616 m 732 s 720 s 763 m 838 m, sh 780 w C–H out of plane bending
857 ms 525 ms 703 s 615 ms 718 m 790 m 718 mw,m Skeletal vibrations
821 ms 652 sh 457 ms 712 s CNC deformation
715 m 522 ms δ(ONO); PA, complex
as, strong; w, weak; m, medium; sh, shoulder; v, very; vs, very strong; br, broad.
bν, stretching; νs, symmetrical stretching; νas, asymmetrical stretching; δ, bending.
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Fig. 4 Infrared spectra of Qui charge-transfer complexes.
Charge-transfer complexes of drug quinidine 871H at C(4)), 2.69–2.75 (t, 2H, CH2 at C(7)), 2.93–3.04 (m, 1H,
CH at C(3)), 3.17–3.18 (d, 2H, J¼4.8 Hz, CH2 at C(2)), 3.89 (s,
3H, OCH3), 4.1–4.12 (m, 1H, CH at C(6)), 5.04–5.07 (2 dd
appears m, 2H, ¼CH2 at C(10)), 5.10 (s, 1H, OH at C(11)), 5.26–
5.29 (m, 1H, CH¼at C(9)), 5.63 (d, 2H, J¼4.8 Hz, phenolic
protons at C(1,2 quinol ring)), 6.05–6.14 (b, 1H, NH+ Hydrogen
bonded), 7.37 (d, 2H, J¼2.8 Hz, phenolic protons at C(3,4 quinol
ring)), 7.37 (s, 1H, CH, at C(5′) quinoline ring), 7.39 (d, 1H,
J¼2.4 Hz, CH, at C(7′) quinoline ring), 7.46 (d, 1H, J¼2.4 Hz,
CH, at C(3′) quinoline ring), 7.49 (d, 1H, J¼4.4 Hz, CH, at C(8′)
quinoline ring), 7.91 (d, 1H, J¼9.2 Hz, CH, at C(2′) quinoline
ring), 8.67 (s, 1H, OH, quinol); [(Qui)(PA)] complex: δ¼1.16–1.18
(m, 1H, CH at C(4)), 1.81–1.95 (m, 4H, 2(CH2) at C(5), C(8)),
2.66–2.68 (t, 2H, CH2 at C(7)), 3.25–3.30 (m, 1H, CH at C(3)),
3.46–3.48 (d, 2H, J¼10.4 Hz, CH2 at C(2)), 3.96 (s, 3H, OCH3),
4.00 (m, 1H, CH at C(6)), 5.21–5.26 (2 dd appears m, 2H, ¼CH2 at
C(10)), 5.94 (s, 1H, OH at C(11)), 6.01–6.10 (m, 1H, CH¼at C(9)),
6.50 (s, 1H, NH+ Hydrogen bonded), 7.31 (s, 1H, CH, at C(5′)
quinoline ring), 7.45 (d, 1H, J¼2.4 Hz, CH, at C(7′) quinoline
ring), 7.48 (d, 1H, J¼2.4 Hz, CH, at C(3′) quinoline ring), 7.62
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Fig. 5 Raman spectra of Qui charge-transfer complexes.
H.H. Eldaroti et al.88(d, 1H, J¼4.8 Hz, CH, at C(8′) quinoline ring), 7.98 (d, 1H,
J¼9.2 Hz, CH, at C(2′) quinoline ring), 8.58 (s, 2H, picrate
protons); [(Qui)(DDQ)] complex: δ¼1.14 (m, 1H, CH at C(4)),
1.79–1.93 (m, 4H, 2(CH2) at C(5), C(8)), 2.65–2.67 (t, 2H, CH2 at
C(7)), 3.22–3.27 (m, 1H, CH at C(3)), 3.42–3.43 (d, 2H, J¼2.8 Hz,
CH2 at C(2)), 3.99 (m, 4H, OCH3, 1H, CH at C(6)), 5.21–5.25
(2 dd appears m, 2H, ¼CH2 at C(10)), 6.01–6.10 (m, 1H, CH¼at
C(9)), 6.21 (s, 1H, NH+), 7.43 (d, 1H, J¼8.8 Hz, CH, at C(7′)
quinoline ring), 7.49 (s, 1H, CH, at C(5′) quinoline ring), 7.62 (d,
1H, J¼4.4 Hz, CH, at C(3′) quinoline ring), 7.96 (d, 1H, J¼9.2
Hz, CH, at C(8′) quinoline ring), 8.75 (d, 1H, J¼4.4 Hz, CH, at C
(2′) quinoline ring).
In the [(Qui)(QL)] complex, the phenolic proton (–OH) signal,
which is observed at approximately δ∼8.59 ppm in the spectrum of
the QL acceptor [29], decreased in intensity with a downﬁeld shift for
the non-hydrogen-bonded one (8.67 ppm) in the spectrum of the CT
complex due to deprotonation from acceptor-to-donor. Besides, the
appearance of the characteristic broad band at 6.05–6.14 ppm, which
is attributed to the formation of (+NH), indicates the involvement of
the N (1) atom of Qui donor and (–OH) group of QL acceptor in
chelating through the deprotonation from the QL acceptor to the Qui
donor. The intensities and chemical shifts of the aromatic signals
were signiﬁcantly affected by the existence of the (N+–H) charge-
transfer interaction between the donor and acceptor molecules. In the
[(Qui)(PA)] complex, it is clearly obvious that, the peak at δ¼11.94
ppm, which is assigned to the (–OH) proton of the free picric acid
acceptor, was absent in the spectrum of this complex, which is
attributed to the formation of the CT complex. Instead, a new peak is
observed at 6.50 ppm in the complex, which is not detected in thespectrum of the free donor, attributing to the proton of (+NH).
Together, these data conﬁrm the formation of intermolecular hydro-
gen bond between PA and Qui [33]. The characteristic signals
presences within the range of 7.31–7.98 ppm were assigned to the
protons (CH) of quinoline ring. It is clearly obvious in [(Qui)(DDQ)]
complex that, the new signal observed at 6.21 in the spectrum of this
complex, which is attributed to the proton of (+NH), conﬁrms that the
(–OH) and (–CRN) groups are primarily involved in the formation
of the CT complex between Qui and DDQ. The migration of the H+
ion from the (–OH) group in the Qui donor to one of the two cyano
groups in the DDQ acceptor resulted in the formation of a positive
ion (–CRN+H), which is associated with the anion O; this result is
also conﬁrmed from the disappearance of the (–OH) signal in the
spectrum of CT complex.3.6. Thermal results
The thermogravimetric analysis (TG) provided information about
the thermal stabilities of the prepared CT complexes and about the
differences in the physical behavior of the starting and resulting
compounds. In order to verify CT interaction between Qui donor
and acceptors and thermal stability of the new CT complexes, the
thermogravimetric analysis of the Qui CT complexes was carried
out over the temperature range of 25–800 1C under an air
atmosphere using 6.83, 8.30 and 11.50 mg samples for [(Qui)
(QL)], [(Qui)(PA)] and [(Qui)(DDQ)] complexes, respectively.
The TG curves were redrawn as mg mass loss versus temperature.
Fig. 7 shows the thermograms for Qui CT complexes and thermal
Fig. 6 1H NMR spectra of (A) [(Qui)(QL)], (B) [(Qui)(PA)] and (C) [(Qui)(DDQ)] complexes.
Charge-transfer complexes of drug quinidine 89analyses data are listed in Table 4. The overall loss of mass from
the TG curves is 95.31% for [(Qui)(QL)], 93.45% for [(Qui)(PA)]
and 65.45% for [(Qui)(DDQ)] complex.
The obtained data indicate that the [(Qui)(QL)] complex is
thermally stable in the range of 25–333 1C. Decomposition of the
complex began at ∼333 1C and ﬁnished at ∼655 1C. The thermal
decomposition of this complex occurs completely in two-steps
within the range of 25–800 1C. The ﬁrst mass loss step occurred
between 25 and 333 1C and is corresponded to the loss of 5C2H2,
2NO2 and 5CO2 molecules with a weight loss of 64.96% very close
to the expected theoretical value of 64.90%. The second degradation
step at 333–800 1C is attributed to the loss of 4C2H2, CO2 and 6H2
molecules, representing a weight loss of (obs.¼30.35, cal.¼
29.46%) with a few carbon atoms remaining as a residual. The
thermal analysis curve of [(Qui)(PA)] complex indicates that
decomposition takes place in two clear decomposition steps within
the 25–800 1C temperature range. The ﬁrst decomposition stepwithin the temperature range 25–308 1C has a weight loss of about
57.21%, and is attributed to the loss of 4C2H2, 3NO2 and 2CO2
molecules. The second decomposition step existed within the 308–
800 1C temperature range, which is assigned by the removal of
6C2H2, NO2, CO2, NH3 and 2H2 molecules with some carbon
atoms remaining as ﬁnal fragment. This step is associated with a
total weight loss of 36.24%, which is in good agreement with the
calculated value (36.67%). The [(Qui)(DDQ)] complex began
decomposing at ∼227 1C in three clear decomposition steps within
the 25–800 1C temperature range. The ﬁrst decomposition step
within the temperature range 25–227 1C corresponds to loss of
2HCN molecules representing a weight loss of 10.53%, which is in
good agreement with the calculated value (9.79%). The second
decomposition step found within the temperature range of 227–
397 1C which is assigned by the removal of Cl2 and 2CO2
molecules represents a weight loss of 19.93% very close to the
expected theoretical value of 20.13%. The last decomposition step
H.H. Eldaroti et al.90has a weight loss of about 34.99%, which is reasonably by the loss
of 3C2H2, 2CO2, 2NH3 and 5H2 molecules. The decomposition of
this complex ended with carbon atoms as a ﬁnal residual.
3.7. Kinetic results
In recent years, there has been increasing interest in determining the
rate-dependent parameters of solid-state non-isothermal decomposi-
tion reactions by analysis of TG curves. Several equations have been
proposed as means of analyzing a TG curve and obtaining values for
kinetic parameters. Two major different methods were used to
evaluate the kinetic thermodynamic parameters: the Coats–Redfern
method and the Horowitz–Metzger method.
The Coats–Redfern equation (Eq. (9)), which is an atypical
integral method, can be represented asZ
0-1
dα=ð1αÞn ¼ ðA=φÞ
Z
T1-T2
eE
n=RTdT ð9Þ
For convenience of integration, the lower limit T1 is usually
taken as zero. After integration, this equation can be represented as
Ln½lnð1αÞ=T2 ¼ En=RT þ ln½AR=φEn ð10Þ
where α is the fraction of the sample decomposed at time t, T is the
derivative peak temperature, A is the frequency factor, R is the gas
constant, E* is the activation energy, and φ is the linear heating rate.0 100 200 300 400 500 600 700 800
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Fig. 7 TG curves of Qui charge-transfer complexes.
Table 4 Thermal decomposition data for the Qui CT complexes.
Complex Stage TG range (1C)
[(Qui)(QL)] C26H30N2O4 I 25–333
II 333–800
Residue –
[(Qui)(PA)] C26H27N5O9 I 25–308
II 308–800
Residue –
[(Qui)(DDQ)] C28H24Cl2N4O4 I 25–227
II 227–397
III 397–800
Residue –A plot of the left-hand side (LHS) against 1/T was constructed and
was found to be linear. E* is the energy of activation in kJ/mol and
was calculated from the slope. The A (s1) value was calculated
from the intercept. The entropy of activation, ΔS* (J/K mol) was
calculated using the equation
ΔSn ¼ R lnðAh=kTsÞ ð11Þ
where k is the Boltzmann constant, h is Planck's constant, and Ts is
the DTG peak temperature.
The Horowitz–Metzger equation (Eq. (12)) was written in the
following form:
log½logðwα=wγÞ ¼ Enθ=2:303RT2slog2:303 ð12Þ
where θ¼TTs, wγ¼wαw, wα is the mass loss at the
completion of the reaction, and w is the mass loss at time t.
The plot of log[log (wα/wγ)] versus θ was constructed and was
observed to be linear, and E* was calculated from its slope. The
pre-exponential factor, A, was calculated from Eq. (13):
Enθ=RT2s ¼ A=½φ expðEn=RTsÞ ð13Þ
From the TG curves, the activation energy, E*, the entropy of
activation, ΔS*, the enthalpy of activation, ΔH*, and the Gibbs
free energy, ΔG*, were calculated from
ΔHn ¼ EnRT and ΔGn ¼ ΔHnTΔSn
The kinetic thermodynamic parameters for the decomposition of
the Qui CT complexes; the activation energy (E*), the frequency
factor (A), the enthalpy of activation (H*), the entropy of activation
(S*) and the free energy of activation (G*) were evaluated
graphically (Fig. 8) by employing the Coats–Redfern and
Horowitz–Metzger methods, and the evaluated data are listed in
Table 5. The kinetic data obtained from the two methods are
comparable and in agreement with each other. The activation
energy (E*) of the complexes is expected to increase with
increasing thermal stability of complexes. Hence, the E* value
for [(Qui)(DDQ)] complex exhibits a higher activation energy
value than other complexes, which indicates the higher thermal
stability of the [(Qui)(DDQ)] complex. Comparing the E* values
for the main decomposition stage of the Qui CT complexes gave
the order DDQ4PA4QL for the different acceptors. These
differences may be caused by the reactivity of the complexesWeight loss (%) Evolved moiety
Found Calculated
64.96 64.90 5C2H2+2NO2+5CO2
30.35 29.46 4C2H2+CO2+6H2
4.69 5.52 Residual carbon
57.21 56.73 4C2H2+3NO2+2CO2
36.24 36.67 6C2H2+NO2+CO2+NH3+2H2
6.55 6.50 Residual carbon
10.53 9.79 2HCN
19.93 20.13 Cl2+2CO2
34.99 35.18 3C2H2+2CO2+2NH3+5H2
34.55 34.82 Residual carbon
Charge-transfer complexes of drug quinidine 91and the electronic conﬁguration of the acceptor when attached to
Qui donor. The calculated E* values using the Coats–Redfern and
Horowitz–Metzger methods for the main decomposition stage of
the complexes are found to be 8.58 104 kJ/mol for [(Qui)(QL)],
9.13 104 kJ/mol for [(Qui)(PA)] and 9.68 104 kJ/mol for
[(Qui)(DDQ)] complex. The entropy of activation (ΔS*) is found
to be of negative values in all the CT complexes which indicate
that the decomposition reactions proceed spontaneously. The ΔS*
values of the Qui CT complexes arranged in decreasing order are
[(Qui)(PA)]4[(Qui)(DDQ)]4[(Qui)(QL)]. The satisfactory values
for the correlation coefﬁcients (r) from the Arrhenius plots of the
thermal decomposition steps were observed to be ∼1 in all cases,
which indicates a good ﬁt with the linear function and reasonable
agreement between the experimental data and the kinetic
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Fig. 8 Kinetic curves for Qui charge-transfer complexes (CR:3.8. Structural interpretation
The structures of the complexes of drug Qui with QL, PA or DDQ
acceptor are conﬁrmed by the elemental analysis, spectrophoto-
metric titration, IR and 1H NMR spectra, and thermal analysis
data. The suggested structures of the CT complexes are given as
shown in Schemes 2–4.3.9. Powder X-ray diffraction characterization
Powder X-ray diffraction (PXRD) studies were carried out for the
[(Qui)(QL)] and [(Qui)(PA)] complexes to demonstrate the crystal-
linity using PANalytical model X'PERT-PRO X-ray powder
diffractometer system. The indexed X-ray diffraction patterns in[
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Table 5 Kinetic parameters determined using the Coats–Redfern (CR) and Horowitz–Metzger (HM).
Complex Stage Method Parameters r
E (kJ/mol) A (s1) ΔS (J/mol K) ΔH (kJ/mol) ΔG (kJ/mol)
[(Qui)(QL)] 1st CR 8.48 104 4.98 106 1.27 102 5.20 104 8.98 104 0.99680
HM 8.68 104 2.91 107 1.82 102 5.87 104 8.68 104 0.99080
[(Qui)(PA)] 1st CR 8.79 104 3.83 109 6.38 10 8.89 104 1.68 104 0.98578
HM 9.46 104 2.68 1010 4.98 10 8.88 104 1.07 104 0.99060
[(Qui)(DDQ)] 1st CR 9.37 104 1.57 104 1.80 102 4.41 104 8.87 104 0.99130
HM 9.98 104 2.49 106 1.28 102 4.81 104 8.66 104 0.99830
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Scheme 2 Suggested structural formula of [(Qui)(QL)] complex.
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Scheme 3 Suggested structural formula of [(Qui)(PA)] complex.
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Scheme 4 Suggested structural formula of [(Qui)(DDQ)] complex.
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Fig. 9 X-ray diffraction pattern for [(Qui)(QL)] and [(Qui)(PA)]
complexes.
H.H. Eldaroti et al.92the range of 51o2θo601 for these two complexes are shown in
Fig. 9. The particle size of these two complexes was estimated
from their PXRD patterns based on the highest intensity value
compared with the other peaks using the well-known Debye–
Scherrer formula given in Eq. (14) [34]:
D¼Kλ=βcos θ ð14Þ
where D is the apparent particle size of the grains, K is a constant
(0.94 for Cu grid), λ is the X-ray wavelength used (1.5406 Å), θ is
half the scattering angle (the Bragg diffraction angle), and β is the
full-width at half-maximum (FWHM) of the X-ray diffraction line
(additional peak broadening) in radians. Table 6 presents the
PXRD spectral data for the [(Qui)(QL)] and [(Qui)(PA)] complexes,
Table 6 PXRD spectral data of [(Qui)(QL)] and [(Qui)(PA)] complexes.
Complex 2θ (deg) d Value (Å) β; FWHM Particle size (nm)
[(Qui)(QL)] 12.694 6.968 0.250 5.827
[(Qui)(PA)] 22.338 3.977 0.225 6.561
Fig. 10 SEM images and EDX spectrum of (A) [(Qui)(QL)], (B) [(Qui)(PA)] and (C) [(Qui)(DDQ)] complexes.
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Table 7 The inhibition diameter zone values (mm) for Qui and its CT complexes.
Sample Inhibition zone diameter (mm/mg sample)
Bacillus subtilis, (G+)a Escherichia coli, (G) Pseudomonas aeuroginosa, (G) Staphylococcus aureus, (G+)
Control: DMSO 0.0 0.0 0.0 0.0
Tetracycline
(antibacterial agent)
34.0 32.0 34.0 30.0
Qui 7.0 6.0 7.0 5.0
[(Qui)(QL)] 13.0 13.0 12.0 12.0
[(Qui)(PA)] 11.0 12.0 13.0 13.0
[(Qui)(DDQ)] 12.0 12.0 12.0 11.0
aG: Gram reaction.
H.H. Eldaroti et al.94including 2θ, β, d (the interplanar spacing between atoms) and D
in nm.
The main characteristic scattering peak of the [(Qui)(QL)] complex
occurs at 12.6941, whereas this peak occurs at 22.3381 in the
diffraction pattern of the [(Qui)(PA)] complex. In the [(Qui)(QL)]
complex, appearances of sharp and strong Bragg peak conﬁrm the
good crystallinity of this complex. The particle size of the complexes
was found to be ∼5.8 and ∼6.7 nm for the [(Qui)(QL)] and [(Qui)
(PA)] complexes, respectively. These values conﬁrmed that the
particle sizes are located within the nanoscale range.
3.10. Morphology characterization
The morphology of the Qui CT complexes was determined using
scanning electron microscopy (SEM). SEM provides general
information about the microstructure, the surface morphology,
the particle size, the chemical composition, and the porous
structures of the surfaces. In addition, the chemical compositions
of the complexes were determined using energy-dispersive X-ray
diffraction (EDX). Fig. 10 shows the SEM surface images of the
[(Qui)(QL)], [(Qui)(PA)] and [(Qui)(DDQ)] complexes along with
their EDX spectra. The formed complexes showed a homogeneous
distribution of each acceptor. The sizes of the particles are quite
different with different acceptors. Most of the complexes particles
exhibit angular shapes with estimated sizes of ∼100 μm. The
particles of the QL complex are tubular-shaped and those of the
PA complex are ﬂake-shaped, whereas the DDQ complex particles
appear as agglomerates and display a large surface area. The peaks
refer to all elements that constitute the molecules of these
complexes; these elements were clearly identiﬁed, and the results
conﬁrmed the proposed structures.
3.11. Biological activity
The antibacterial activity of the Qui and its complexes were
screened in vitro against two Gram-positive bacterial strains,
Staphylococcus aureus (S. aureus) and Bacillus subtilis, and two
Gram-negative bacterial strains, Escherichia coli (E. coli) and
Pseudomonas aeruginosa (P. aeruginosa). The CT complexes to
be tested were dissolved in DMSO to obtain 100 μg/mL stock
solutions. The activity was determined by measuring the inhibition
zone diameter values (mm) of the complexes against the micro-
organisms. Tetracycline was used as the positive control. The
screening data are listed in Table 7. The results indicated that the
Qui complexes exhibited moderate inhibitory results against all ofthe Gram-positive and Gram-negative bacterial species, as reported
in Table 7. It is obvious that the biological activity of the Qui CT
complexes is more than that of free Qui drug.
In addition, the biological activity of the Qui drug and its
complexes are lower than tetracycline standard.4. Conclusion
Qui is well known as medicinally important compound. This paper
described the CT complexes of Qui with three acceptors. The
synthesized CT complexes were characterized using various spectro-
scopic techniques including UV–visible, IR, Raman, 1H NMR
spectroscopy and X-ray diffraction as well as scanning electron
microscopy and thermogravimetric (TG) analyses. It is observed that
the reaction stoichiometry is 1:1, and the resulting CT complexes
were shown to have the general formula: [(Qui)(acceptor)]. The
obtained complexes are nanoscale, semi-crystalline material, ther-
mally stable and spontaneous. Physical and kinetic parameters such
as formation constant (KCT), molar extinction coefﬁcient (εCT) and
other spectroscopic data have been estimated. The CT complexes
were also screened for their antibacterial activities using the disc
diffusion method, and it is obvious that the antibacterial activity of the
Qui CT complexes is more than that of free Qui drug.
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